Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by qPCR and viral culture were performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAb resulted in rapid clearance of culturable virus in participants without treatment-emergent resistance. One day after treatment, 0 of 28 (0%) participants receiving mAb and 16 of 39 (41%) receiving placebo still had culturable virus (p <0.0001); nasal viral loads were only modestly lower in the mAb-treated group at days 2 and 3. Recrudescence of culturable virus was detected in three participants with emerging mAb resistance and viral load rebound. The rapid reduction in shedding of viable SARS-CoV-2 after mAb treatment highlights the potential role of mAbs in preventing disease transmission.
| Errataetall: |
UpdateIn: Cell Rep Med. 2022 Jun 20;:100678. - PMID 35793677 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 30. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boucau, Julie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.08.2022 published: Electronic UpdateIn: Cell Rep Med. 2022 Jun 20;:100678. - PMID 35793677 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.12.25.21268211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335533787 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335533787 | ||
| 003 | DE-627 | ||
| 005 | 20231225230051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.25.21268211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335533787 | ||
| 035 | |a (NLM)35018382 | ||
| 035 | |a (PII)2021.12.25.21268211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boucau, Julie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.08.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cell Rep Med. 2022 Jun 20;:100678. - PMID 35793677 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by qPCR and viral culture were performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAb resulted in rapid clearance of culturable virus in participants without treatment-emergent resistance. One day after treatment, 0 of 28 (0%) participants receiving mAb and 16 of 39 (41%) receiving placebo still had culturable virus (p <0.0001); nasal viral loads were only modestly lower in the mAb-treated group at days 2 and 3. Recrudescence of culturable virus was detected in three participants with emerging mAb resistance and viral load rebound. The rapid reduction in shedding of viable SARS-CoV-2 after mAb treatment highlights the potential role of mAbs in preventing disease transmission | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Chew, Kara W |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Deo, Rinki |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, James |e verfasserin |4 aut | |
| 700 | 1 | |a Flynn, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Crain, Charles R |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Ritz, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Moser, Carlee |e verfasserin |4 aut | |
| 700 | 1 | |a Dragavon, Joan A |e verfasserin |4 aut | |
| 700 | 1 | |a Javan, Arzhang C |e verfasserin |4 aut | |
| 700 | 1 | |a Nirula, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Klekotka, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Greninger, Alexander L |e verfasserin |4 aut | |
| 700 | 1 | |a Coombs, Robert W |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, William A |c 2nd |e verfasserin |4 aut | |
| 700 | 1 | |a Daar, Eric S |e verfasserin |4 aut | |
| 700 | 1 | |a Wohl, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Eron, Joseph J |e verfasserin |4 aut | |
| 700 | 1 | |a Currier, Judith S |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Davey M |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jonathan Z |e verfasserin |4 aut | |
| 700 | 1 | |a Barczak, Amy K |e verfasserin |4 aut | |
| 700 | 0 | |a ACTIV-2/A5401 Study Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 30. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.25.21268211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||